Praxis Precision Medicine

Bewertungs-Analyse

Über das Unternehmen

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molec

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich Praxis Precision Medicine kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.